$XTALPI(02228.HK) Crystal Technology, a U.S. pharmaceutical company (Eli Lilly) insider feedback latest news:

1. This company has technical cooperation with leading pharmaceutical companies worldwide, and the intended contract amounts are quite good;

2. The feedback collected by this company indicates that the technology is good and there has been progress;

3. In terms of pharmaceutical milestones, it is still in the early stages and has not secured enough contract performance payments;

4. The company's operating cash flow pressure is quite high, which reflects that the company's valuation is relatively high;

5. Domestic institutions are speculating on scarcity, and currently, domestic institutions have a relatively large position.

Trading judgment: Currently, the stock price still has support. For those who have not built a position, if interested in this sector, it can be bought. However, it is indeed not the time to continue large-scale buying. For me, I may need to wait one or two months. Because I am currently considering if it is sufficiently positive, the target position will be 5 million shares.